Urinary dipstick findings and UTI risk with SGLT2 inhibitors: a post-hoc analysis of the CANVAS and CREDENCE trials

Yohei Doi, Takayuki Hamano, Mayumi Fukuda-Doi, Yoshitaka Isaka · 2026

Read Urinary dipstick findings and UTI risk with SGLT2 inhibitors: a post-hoc analysis of the CANVAS and CREDENCE trials by Yohei Doi, Takayuki Hamano, Mayumi Fukuda-Doi, Yoshitaka Isaka (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13624796.txt.

Description

Yohei Doi, Takayuki Hamano, Mayumi Fukuda-Doi, and Yoshitaka Isaka revisit two large drug trials, in a paper published in 2026. The drug, canagliflozin, treats type 2 diabetes and helps heart and kidneys, but fear of urine infections may limit its use. The team asked whether a simple urine dipstick test predicts who will get such an infection.

They pooled data from 8,614 trial patients. About one in ten had an abnormal result for white cells in urine, and far fewer for nitrite. Stronger abnormal results meant higher infection risk in the months ahead. The drug itself, though, did not raise infection risk versus placebo, in either urine group. The authors say dipstick results mark risk but should not by themselves block a useful drug.

Catalog record

CREATORYohei Doi, Takayuki Hamano, Mayumi Fukuda-Doi, Yoshitaka Isaka
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE32 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13624796

Browse the full library · About the Tower of Babel